Stock comparison
ResMed
Taysha Gene Therapies
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
TSHA
Taysha Gene Therapies
Market cap
$1.37B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TSHA | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 41D | RMD |
| Benjamin Graham | 75B | 56D | RMD |
| Philip Fisher | 75B | 61C | RMD |
| Peter Lynch | 58C | 5F | RMD |
| Joel Greenblatt | 47D | 2F | RMD |
| Charlie Munger | 69B | 57D | RMD |
| Terry Smith | 73B | 58D | RMD |
Side-by-side metrics
| Metric | RMD | TSHA |
|---|---|---|
| Market cap | $30.18B | $1.37B |
| P/E (TTM) | 19.6x | - |
| EV/EBIT | 17.1x | - |
| ROIC (TTM) | 19.63% | -47.3% |
| Gross margin | 61.69% | 88.22% |
| Net margin | 27.44% | -17.38% |
| Revenue CAGR 5y | 12.64% | - |
| EPS CAGR 5y | 30.73% | - |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- ROIC (TTM)19.63%vs -47.3%+141%
- Net margin27.44%vs -17.38%+102%
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $1.37B+95%
TSHA leads on
- P/E (TTM)-vs 19.6x+179%
- EV/EBIT-vs 17.1x+159%
- Debt / Equity0.1xvs 0.1x+35%
- Gross margin88.22%vs 61.69%+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.